Researchers at the RIKEN BioResource Research Center, Kyoto, Japan, have reported that retinal organoids, derived from patients’ induced pluripotent stem cells (iPSCs) with a EYS… Read More »Retinal dystrophy caused by EYS dysfunction in retinal organoids shows significant phototoxicity from RIKEN research.
Dear EURETINA Members, A very warm welcome to the May 10th, 2024 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue… Read More »May 10th, 2024 “EURETINA-Brief”© Issue No. 291
A US company, LumiThera Inc., based in Seattle, WA, has announced a multi-centre clinical registry study to enroll up to 1,000 AMD patients with their… Read More »LumiThera Inc. have announced a multi-centre registry (“EUROLIGHT”) for their photo-biomodulation (PBM) treatment of dry AMD across up to 20 European centres.
A review from the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has reported that “orphan designations” (OD) on inherited retinal… Read More »The EMA Committee for Orphan Medicinal Products (COMP) propose a new approach to Orphan Designations (OD) on inherited retinal degenerations (IRDs).
Researchers at the Department of Ophthalmology, University of Turin, Italy, have reported a significant association between OCT biomarker measurements and reading performance in patients with… Read More »Association of retinal OCT biomarkers with reading performance in patients with diabetic macular edema (DME).
Dear EURETINA Members, A very warm welcome to the April 26th, 2024 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue… Read More »April 26th 2024 “EURETINA-Brief”© Issue No. 290
A report in Retina Today, entitled, “A new perspective on the retina wage gap”, by Aidan Gilson, BS and Ron Adelman, MD, MPH, MBA, showed… Read More »A report from authors at the Yale School of Medicine suggest that disparities persist between female and male retina specialists.
The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) have announced a positive opinion for the granting of a marketing authorisation for… Read More »EMA (European Medicines Agency) approves authorisation of ocular formulation of bevacizumab AMD.
Researchers at the Moorfields Eye Hospital and UCL Institute of Ophthalmology, University College London, UK, have reported the natural history of a retinopathy associated with… Read More »Natural history and characteristics of IQCB1(NPHP5) retinopathy may aim to measure relevant subsequent research outcomes.
Dear EURETINA Members, A very warm welcome to the April 12th, 2024 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue… Read More »April 12th, 2024 “EURETINA-Brief”© Issue No. 289
